|
Dr. Marantz obtained a B.S. in Chemistry followed by an M.S. in Biochemistry from Tel Aviv University. She returned to Tel Aviv University to complete a Ph.D. where she focused on the fields of proton transfer dynamics and computational biology. In 2000 Dr. Marantz joined the founders of Predix Pharmaceuticals as a key scientist and began leading the computational screening department in 2002. In her current role she leads EPIX's computational drug discovery team which is responsible for the identification of all of early discovery product candidates. During her time at EPIX Dr. Marantz has co- authored 6 peer-reviewed publications 2 issued U.S. patents and an additional 15 pending-patent applications in the US.
| 